Alzheimer’s disease
Researchers from around the world are coming to present scientific research and clinical trial data for the disease.
The 12th Clinical Trials on Alzheimer’s Disease conference kicks off today. One of the big stories, which will be presented on Thursday, December 5, is detailed results from Biogen’s Phase III clinical trials of aducanumab.
There are many challenges to tackling neurological diseases like Alzheimer’s, but one is the difficulty in developing drugs that can cross the blood-brain barrier. Researchers may have found a way around that problem.
TauRx analyzed the relationship between the treatment doses, blood levels and pharmacological activity of the drug on the brain in more than 1,000 patients with mild-to-moderate Alzheimer’s disease as part of two Phase III global clinical trials.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
What is the best way to prevent or even reverse Alzheimer’s disease? That’s the question at the top of many researchers’ minds, especially given all of the recent large Phase 3 failures involving beta-amyloid targeting drugs, the most pursued target to date. This is troubling but not entirely shocking.
Reuters reports that the turnaround was built on “top secret” meetings, non-disclosure agreements and six months of researchers, regulators and statisticians churning the data on a larger dataset that included a total of 3,285 patients.
The decision was based on new analysis run by Biogen in consultation with the FDA of a larger dataset from the trials halted in March.
50 million people worldwide live with symptomatic Alzheimer’s, which has no cure. In honor of September 21st being World Alzheimer’s Day, we evaluated the current therapies, drugs in the pipeline and disease outlook.
PRESS RELEASES